3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Sarcoma
1
Neoplasm Metastasis
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Doxorubicin
25
Radiotherapy
16
apatinib
15
Cyclophosphamide
15
Ifosfamide
13
anlotinib
12
camrelizumab
10
Temozolomide
9
Imatinib Mesylate
9
Vincristine
8
Surgical Procedures, Operative
7
Neoadjuvant Therapy
7
Methotrexate
7
Drug Therapy
7
Dactinomycin
5
Blood Specimen Collection
5
fludarabine phosphate
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
Etoposide
4
Docetaxel
4
Carboplatin
4
toripalimab
3
pembrolizumab
3
Trabectedin
3
Topotecan
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Nivolumab
3
Melphalan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug Combinations
×
Sarcoma
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled